Common Contracts
20 similar Open Market Sale Agreement contracts by Calithera Biosciences, Inc., General Maritime Corp / MI, Verona Pharma PLC, others
OPEN MARKET SALE AGREEMENTOpen Market Sale Agreement • March 22nd, 2024 • Adicet Bio, Inc. • Pharmaceutical preparations • New York
Adicet Bio, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.0001 per share (the “Common Shares”), on the terms set forth in this agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENTOpen Market Sale Agreement • March 7th, 2023 • Verona Pharma PLC • Pharmaceutical preparations • New York
OPEN MARKET SALE AGREEMENT SMOpen Market Sale Agreement • September 2nd, 2022 • Northwest Pipe Co • Steel pipe & tubes • New York
Northwest Pipe Company, an Oregon corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.01 per share (the “Common Shares”), on the terms set forth in this agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENTOpen Market Sale Agreement • May 24th, 2022 • Finch Therapeutics Group, Inc. • Biological products, (no disgnostic substances) • New York
OPEN MARKET SALE AGREEMENTOpen Market Sale Agreement • March 18th, 2022 • Decibel Therapeutics, Inc. • Pharmaceutical preparations • New York
OPEN MARKET SALE AGREEMENTOpen Market Sale Agreement • March 14th, 2022 • Spruce Biosciences, Inc. • Pharmaceutical preparations • New York
Spruce Biosciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.0001 per share (the “Common Shares”), having an aggregate offering price of up to $21,000,000 on the terms set forth in this agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENT SMOpen Market Sale Agreement • February 11th, 2022 • Vascular Biogenics Ltd. • Pharmaceutical preparations • New York
OPEN MARKET SALE AGREEMENTOpen Market Sale Agreement • August 3rd, 2021 • Esperion Therapeutics, Inc. • Pharmaceutical preparations • New York
Esperion Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.001 per share (the “Common Shares”), having an aggregate offering price of up to $250,000,000 on the terms set forth in this agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENT SMOpen Market Sale Agreement • June 4th, 2021 • Ayala Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
Board of Directors or committees, the Company has provided Davis Polk & Wardwell LLP and Latham & Watkins LLP with originals or true, correct and complete copies of draft minutes or written agendas relating thereto, which drafts and agendas, if any, reflect all material events that occurred in connection with such proceedings. There have been no material changes, additions or alterations in said minute books, records and other documents that have not been disclosed to Davis Polk & Wardwell LLP or Latham & Watkins LLP in writing.
OPEN MARKET SALE AGREEMENTOpen Market Sale Agreement • March 19th, 2021 • Verona Pharma PLC • Pharmaceutical preparations • New York
OPEN MARKET SALE AGREEMENTOpen Market Sale Agreement • August 10th, 2020 • Calithera Biosciences, Inc. • Pharmaceutical preparations • New York
OPEN MARKET SALE AGREEMENT SMOpen Market Sale Agreement • August 10th, 2020 • Turning Point Therapeutics, Inc. • Pharmaceutical preparations • New York
OPEN MARKET SALE AGREEMENTOpen Market Sale Agreement • March 13th, 2020 • Aclaris Therapeutics, Inc. • Pharmaceutical preparations • New York
Aclaris Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.00001 per share (the “Common Shares”), having an aggregate offering price of up to $25,000,000 on the terms set forth in this agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENTOpen Market Sale Agreement • March 11th, 2020 • Calithera Biosciences, Inc. • Pharmaceutical preparations • New York
OPEN MARKET SALE AGREEMENTOpen Market Sale Agreement • December 6th, 2019 • Calithera Biosciences, Inc. • Pharmaceutical preparations • New York
OPEN MARKET SALE AGREEMENTOpen Market Sale Agreement • August 2nd, 2019 • Constellation Pharmaceuticals Inc • Pharmaceutical preparations • New York
OPEN MARKET SALE AGREEMENT SMOpen Market Sale Agreement • June 9th, 2017 • Zynerba Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
OPEN MARKET SALE AGREEMENT SMOpen Market Sale Agreement • September 1st, 2016 • Zynerba Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
OPEN MARKET SALE AGREEMENTOpen Market Sale Agreement • June 9th, 2011 • General Maritime Corp / MI • Deep sea foreign transportation of freight • New York
OPEN MARKET SALE AGREEMENTOpen Market Sale Agreement • June 9th, 2011 • General Maritime Corp / MI • Deep sea foreign transportation of freight • New York
